Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
DTCFF Stock Chart & Stats
$0.58
$0.06(15.36%)
At close: 4:00 PM EST
$0.58
$0.06(15.36%)
Day’s Range― - ―
52-Week Range$0.31 - $0.78
Previous CloseN/A
Volume8.00K
Average Volume (3M)599.00
Market Cap
$27.07M
Enterprise Value$27.30M
Total Cash (Recent Filing)$2.95M
Total Debt (Recent Filing)$1.56M
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume40
30 Day Avg. Volume599
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-504.09
Enterprise Value/Ebitda-6.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformThe Accum® platform targets intracellular delivery and potency enhancement for biologics across oncology and infectious disease. A platform-style asset can generate multiple pipeline candidates, support partnerships or licensing, and create durable differentiation versus single-product developers.
Improving Loss TrendA marked reduction in annual losses shows the company has been able to lower spending or improve efficiency. If sustained, this trend extends runway, reduces near-term financing needs, and reflects stronger operational discipline—important for a development-stage biotech reliant on funding.
Positive Equity CushionPositive equity and increased total assets provide a balance-sheet buffer against development setbacks. This improves solvency metrics versus prior years, enhancing the company's ability to negotiate financing or collaborations on better terms and supports continued R&D investment.
Bears Say
No RevenueBeing pre-revenue means the company cannot self-fund operations and remains entirely dependent on external capital. This structural state increases execution risk until a clinical or commercial milestone proves the technology can generate sales and cover development costs.
Persistent Cash BurnSustained negative operating and free cash flow indicate ongoing cash consumption to fund development. This necessitates periodic capital raises, which can dilute shareholders, constrain long-term program funding, and increase risk if market access to financing tightens.
Financing/Dilution RiskA history of negative equity combined with nontrivial debt highlights past solvency stress and ongoing leverage. This elevates refinancing and dilution risk, potentially forcing equity issuances or unfavorable financing that could limit strategic flexibility and shareholder value over time.
Defence Therapeutics News
DTCFF FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.31 and its highest was $0.78 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $27.07M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 133 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.036.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---